X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Product Name: NMRA-140
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BlackThorn Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
The funding will support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates including BTRX-335140 (NMRA-140) for neuropsychiatric disorders and neurodegenerative diseases and the development of precision neuroscience platform.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Product Name: BTRX-335140
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abu Dhabi Growth Fund
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
